36 related articles for article (PubMed ID: 11741176)
1. Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR gamma ligand troglitazone.
Kawa S; Nikaido T; Unno H; Usuda N; Nakayama K; Kiyosawa K
Pancreas; 2002 Jan; 24(1):1-7. PubMed ID: 11741176
[TBL] [Abstract][Full Text] [Related]
2. Activation of PPARγ and inhibition of cell proliferation reduces key proteins associated with the basal subtype of bladder cancer in As3+-transformed UROtsa cells.
Mehus AA; Bergum N; Knutson P; Shrestha S; Zhou XD; Garrett SH; Sens DA; Sens MA; Somji S
PLoS One; 2020; 15(8):e0237976. PubMed ID: 32822399
[TBL] [Abstract][Full Text] [Related]
3. Functional network analysis of gene-phenotype connectivity based on pioglitazone.
Wang W; Zhang L; Wang X; Lin D; Pan Q; Guo L
Exp Ther Med; 2019 Dec; 18(6):4790-4798. PubMed ID: 31798704
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor-γ agonist-mediated inhibition of cell growth is independent of apoptosis in human epidermoid carcinoma A431 cells.
Li Q; Peng YS; Chen PJ; Wang ML; Cao C; Xiong H; Zhang J; Chen MH; Peng XB; Zeng K
Oncol Lett; 2018 May; 15(5):6578-6584. PubMed ID: 29725405
[TBL] [Abstract][Full Text] [Related]
5. Deciphering the Roles of Thiazolidinediones and PPAR
Chiu M; McBeth L; Sindhwani P; Hinds TD
PPAR Res; 2017; 2017():4810672. PubMed ID: 28348577
[TBL] [Abstract][Full Text] [Related]
6. 15-Deoxy-Δ(12,14)-prostaglandin J2 Induces Apoptosis and Upregulates SOCS3 in Human Thyroid Cancer Cells.
Trindade-da-Silva CA; Reis CF; Vecchi L; Napimoga MH; Sperandio M; Matias Colombo BF; Alves PT; Ward LS; Ueira-Vieira C; Goulart LR
PPAR Res; 2016; 2016():4106297. PubMed ID: 27190500
[TBL] [Abstract][Full Text] [Related]
7. Transcriptome Profiling of Caco-2 Cancer Cell Line following Treatment with Extracts from Iodine-Biofortified Lettuce (Lactuca sativa L.).
Koronowicz AA; Kopeć A; Master A; Smoleń S; Piątkowska E; Bieżanowska-Kopeć R; Ledwożyw-Smoleń I; Skoczylas Ł; Rakoczy R; Leszczyńska T; Kapusta-Duch J; Pysz M
PLoS One; 2016; 11(1):e0147336. PubMed ID: 26799209
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy and chemoprevention by thiazolidinediones.
Fröhlich E; Wahl R
Biomed Res Int; 2015; 2015():845340. PubMed ID: 25866814
[TBL] [Abstract][Full Text] [Related]
9. Can an oral antidiabetic (rosiglitazone) be of benefit in leukemia treatment?
Cetinkalp S; Simsir IY; Sahin F; Saydam G; Ural AU; Yilmaz C
Saudi Pharm J; 2015 Jan; 23(1):14-21. PubMed ID: 25685038
[TBL] [Abstract][Full Text] [Related]
10. Pioglitazone inhibits the proliferation and metastasis of human pancreatic cancer cells.
Ninomiya I; Yamazaki K; Oyama K; Hayashi H; Tajima H; Kitagawa H; Fushida S; Fujimura T; Ohta T
Oncol Lett; 2014 Dec; 8(6):2709-2714. PubMed ID: 25364454
[TBL] [Abstract][Full Text] [Related]
11. Role of Peroxisome Proliferator-Activated Receptor β/δ and B-Cell Lymphoma-6 in Regulation of Genes Involved in Metastasis and Migration in Pancreatic Cancer Cells.
Coleman JD; Thompson JT; Smith RW; Prokopczyk B; Vanden Heuvel JP
PPAR Res; 2013; 2013():121956. PubMed ID: 23737761
[TBL] [Abstract][Full Text] [Related]
12. The PPARγ agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency.
Nakles RE; Kallakury BV; Furth PA
Am J Pathol; 2013 Jun; 182(6):1976-85. PubMed ID: 23664366
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic implications of targeting energy metabolism in breast cancer.
Sakharkar MK; Shashni B; Sharma K; Dhillon SK; Ranjekar PR; Sakharkar KR
PPAR Res; 2013; 2013():109285. PubMed ID: 23431283
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor gamma and regulations by the ubiquitin-proteasome system in pancreatic cancer.
Stravodimou A; Mazzoccoli G; Voutsadakis IA
PPAR Res; 2012; 2012():367450. PubMed ID: 23049538
[TBL] [Abstract][Full Text] [Related]
15. The insulin receptor: a new target for cancer therapy.
Malaguarnera R; Belfiore A
Front Endocrinol (Lausanne); 2011; 2():93. PubMed ID: 22654833
[TBL] [Abstract][Full Text] [Related]
16. Troglitazone reverses the multiple drug resistance phenotype in cancer cells.
Davies GF; Juurlink BH; Harkness TA
Drug Des Devel Ther; 2009 Sep; 3():79-88. PubMed ID: 19920924
[TBL] [Abstract][Full Text] [Related]
17. PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancer.
Belfiore A; Genua M; Malaguarnera R
PPAR Res; 2009; 2009():830501. PubMed ID: 19609453
[TBL] [Abstract][Full Text] [Related]
18. The Role of PPARgamma Receptors and Leukotriene B(4) Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer.
Adrian TE; Hennig R; Friess H; Ding X
PPAR Res; 2008; 2008():827096. PubMed ID: 19190780
[TBL] [Abstract][Full Text] [Related]
19. The Role of PPAR Ligands in Controlling Growth-Related Gene Expression and their Interaction with Lipoperoxidation Products.
Barrera G; Toaldo C; Pizzimenti S; Cerbone A; Pettazzoni P; Dianzani MU; Ferretti C
PPAR Res; 2008; 2008():524671. PubMed ID: 18615196
[TBL] [Abstract][Full Text] [Related]
20. The Role of PPAR-gamma and Its Interaction with COX-2 in Pancreatic Cancer.
Eibl G
PPAR Res; 2008; 2008():326915. PubMed ID: 18615182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
